STERIS plc (STE) Stock Analysis

STERIS’s primary competitive advantage is its high-recurrence, compliance-driven business model. Over 75% of revenue is recurring, derived from consumables and services tied to a large installed base of sterilization equipment in hospitals and medical device manufacturers. This creates significant switching costs: replacing STERIS systems requires not only capital outlay but also operational disruption, staff retraining, and regulatory re-validation. As a result, customer relationships are exceptionally sticky and long-lived.

The company’s scale is a further advantage. STERIS operates over 100 manufacturing and service sites and more than 60 contract sterilization facilities globally, enabling redundancy and reliability that smaller competitors cannot match. In the Applied Sterilization Technologies segment, this network allows STERIS to shift customer volume between sites, minimizing downtime—a key differentiator versus rivals like Sotera Health (Sterigenics).

Regulatory barriers are substantial. Both STERIS and competitors such as Getinge and Fortive’s ASP must meet stringent FDA and international standards, but STERIS’s track record and breadth of regulatory expertise reinforce customer trust and deter new entrants.

Compared to Getinge, STERIS has a stronger North American presence and a more extensive service network. Against Stryker and Becton Dickinson, STERIS’s focus on infection prevention and integrated solutions yields higher recurring revenue and customer lock-in, though it lacks their scale in other product categories.

Overall, STERIS’s moat is rooted in switching costs, regulatory complexity, and operational scale, supporting durable profitability and customer retention.